Olatec

Olatec is a privately held biopharmaceutical company that has developed a safe, orally administered NLRP3 antagonist therapy platform for the treatment and prevention of a broad spectrum of acute and chronic inflammatory diseases mediated by interleukin-1 (IL-1). These include heart failure, asthma, Alzheimer's disease, multiple sclerosis, type 2 diabetes, melanoma, breast cancer, and more. By selectively targeting NLRP3 (the first line of response in the human innate immune system), Olatec’s lead compound dapansutrile (laboratory code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL-1β and IL-18. Olatec’s drug development team, which has collaborated for over 10 years, consists of experienced management and international thought leaders with unparalleled expertise in inflammation and immunology. They have contributed to the discovery and development of some of today’s leading inflammation treatments on the market.